The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
暂无分享,去创建一个
J. Taube | C. Drake | G. Netto | A. Baras | A. Meeker | M. Schoenberg | M. Kates | T. Bivalacqua | Jen‐Jane Liu | N. Gandhi | M. O. Hoque | N. Hahn
[1] R. Bernards,et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. , 2016, European urology.
[2] L. Marchionni,et al. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma , 2015, PloS one.
[3] J. Taube,et al. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade , 2015, Clinical Cancer Research.
[4] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[5] J. Taube,et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. , 2015, Urology.
[6] S. Faraj,et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. , 2015, Urologic oncology.
[7] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[8] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[9] A. Apolo,et al. Targeted therapies in urothelial carcinoma , 2014, Current opinion in oncology.
[10] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[11] K. Baggerly,et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.
[12] Kai Wang,et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy , 2014, Modern Pathology.
[13] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[14] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[15] Y. Kluger,et al. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases , 2014, Journal of Cancer.
[16] R. Thompson,et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] M. Fernö,et al. Toward a molecular pathologic classification of urothelial carcinoma. , 2013, The American journal of pathology.
[18] K. Jang,et al. Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. , 2013, Translational oncology.
[19] Johan Staaf,et al. Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma , 2012, PloS one.
[20] Mårten Fernö,et al. A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.
[21] R. deLeeuw,et al. The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.
[22] H. Zhan,et al. Presence of tumour-infiltrating FOXP3+ lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[23] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[24] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[25] C. Drake,et al. Immunotherapy earns its spot in the ranks of cancer therapy , 2012, The Journal of experimental medicine.
[26] R. Moll,et al. Localization of FOXP3-positive cells in renal cell carcinoma , 2012, Tumor Biology.
[27] O. Winqvist,et al. FOXP3 and survival in urinary bladder cancer , 2011, BJU international.
[28] B. Czerniak,et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. , 2010, Urologic oncology.
[29] Mattias Höglund,et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. , 2010, Cancer research.
[30] Mahul B Amin,et al. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications , 2009, Modern Pathology.
[31] N. Marcussen,et al. Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[32] S. Boorjian,et al. T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival , 2008, Clinical Cancer Research.
[33] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[34] Torben F. Ørntoft,et al. Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer , 2007, Clinical Cancer Research.
[35] Haidong Dong,et al. PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.
[36] R. Millikan,et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. , 2007, Urology.
[37] P. Mischel,et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.
[38] R. Thompson,et al. Significance of B7-H1 overexpression in kidney cancer. , 2006, Clinical genitourinary cancer.
[39] J. Cheville,et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.
[40] C. Vale. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .
[41] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[42] M. Soloway,et al. Contemporary management of stage T1 transitional cell carcinoma of the bladder. , 2002, The Journal of urology.
[43] K. Kihara,et al. [Neoadjuvant chemotherapy for invasive bladder cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.
[44] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.